TCMD

TactileA

Nasdaq / Health Care Equipment & Services

At close

2026-07-23

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$39.50

+44.0% vs current

Most likely

Base case

50%

Probability

Target price

$30.00

+9.3% vs current

B-

Bear case

30%

Probability

Target price

$24.00

-12.5% vs current

AI sentiment snapshot

Latest data as of 2026-07-16

AI commentary

Recent packet news is mildly positive around Q1 execution and the MyoSleeve update, but coverage remains thin and no dependable analyst-revision, options, short-interest, employee, or social dataset is supplied. Primary evidence supports monitoring rather than a high-conviction bullish view.

RankAlpha Sentiment Codex - 2026-07-16

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-04catalystQ1 2026 operating improvementHigh impact

Q1 revenue grew 23% year over year to $75.3 million, gross margin expanded to 76.5%, and adjusted EBITDA turned positive at $3.7 million. Full-year revenue guidance was modestly raised, but the May earnings reset is likely substantially priced in. [#SEC-8K-2026-05-04]

2026-07-13eventMyoSleeve portfolio expansionMedium impact

The company disclosed that MyoSleeve adds a treatment option for appropriately selected patients in earlier stages of chronic swelling, broadening its established portfolio. Commercial adoption remains unproven. [#8-K-2026-07-13]

2027-07-16catalystReimbursement and platform executionHigh impact

Expanded AI-enabled order-management capabilities for Medicare prior authorization, continued lymphedema and airway-clearance momentum, and portfolio additions could support growth and operating leverage. The timing and magnitude of benefits are uncertain. [#SEC-8K-2026-05-04]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-07-16 • Updated nightlySource: Internal modelMethodology